Gastric cancer is one of the leading causes of cancer-related death worldwide. Many
patients have inoperable disease at diagnosis or have recurrent disease after resection with …

Less than a century ago, gastric cancer was the most common cancer in the United States
and perhaps throughout the world. Despite its worldwide decline in incidence over the past …

The NCCN Clinical Practice Guidelines in Oncology for Genetic/Familial High-Risk
Assessment: Breast and Ovarian provide recommendations for genetic testing and …

BACKGROUND As panel testing becomes more common in clinical practice, it is important
to understand the prevalence and trends associated with the pathogenic variants (PVs) …

Importance E-cadherin (CDH1) is a cancer predisposition gene mutated in families meeting
clinically defined hereditary diffuse gastric cancer (HDGC). Reliable estimates of cancer risk …

BACKGROUND Next‐generation sequencing (NGS) allows for simultaneous sequencing of
multiple cancer susceptibility genes and, for an individual, may be more efficient and less …

Purpose Multiple-gene sequencing is entering practice, but its clinical value is unknown. We
evaluated the performance of a customized germline-DNA sequencing panel for cancer-risk …

Cell-free DNA (cfDNA) is easily accessible in peripheral blood and can be used as
biomarkers for cancer diagnostics, prognostics, and therapeutics. The applications of cfDNA …

Breast cancer is the most common malignancy among females. 5%–10% of breast cancer
cases are hereditary and are caused by pathogenic mutations in the considered reference …

Gastric adenocarcinoma (GC) is the third leading cause of global cancer mortality, and the
leading infection-associated cancer with more than 1 million incident cases annually and …